Logo

Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe

Share this
Ionis

Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe

Shots:

  • Under the agreement, Ionis gains right for the preclinical and clinical development of donidalorsen while Otsuka holds exclusive commercialization rights in the EU along with its regulatory filings
  • Ionis is eligible for a $65M upfront payment, milestone payments tied to regulatory and sales targets, and tiered royalties (20% to 30% based on annual net sales) for donidalorsen. It anticipates launching donidalorsen in the US upon approval, independently
  • Additionally, Ionis revealed 2yr. P-II open-label extension (OLE) study data that indicated a 96% overall sustained mean reduction in baseline HAE attack rates with donidalorsen. The P-III study data is anticipated in H1’24

Ref: Ionis Image: Ionis

Related News:- Ionis Pharmaceuticals Reports the Results for Donidalorsen in P-II Trial to Treat Type 1 and Type 2 Hereditary Angioedema

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions